Global Rheumatoid Arthritis Drugs Market 2018-2022
About this market
The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA. Technavio’s analysts have predicted that the rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.
Increasing need for affordable biologics for rheumatoid arthritis
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.
Low access to healthcare due to social stigma
Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.
For the detailed list of factors that will drive and challenge the growth of the rheumatoid arthritis drugs market during the 2018-2022, view our report.
The market appears to be fragmented and with the presence of several companies including Amgen and Novartis the competitive environment is quite intense. Factors such as the use of biologics and biosimilars for the treatment of RA and increasing need for affordable biologics for rheumatoid arthritis, will provide considerable growth opportunities to rheumatoid arthritis drugs manufactures. AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Many established rheumatoid arthritis drug companies are vying for their share of the global rheumatoid arthritis drugs market, and players must differentiate themselves to gain vital traction over their competitors.’
Technavio Announces the Publication of its Research Report – Global Rheumatoid Arthritis Drugs Market 2018-2022
Technavio recognizes the following companies as the key players in the global rheumatoid arthritis drugs market: AbbVie, Amgen, Novartis, Pfizer, UCB Pharma, and Johnson & Johnson.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the use of biologics and biosimilars for the treatment of RA.”
According to the report, one of the major drivers for this market is the increasing need for affordable biologics for rheumatoid arthritis.
Further, the report states that one of the major factors hindering the growth of this market is the low access to healthcare due to social stigma.
Johnson & Johnson
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook